
1. vaccine. 2015 mar 24;33(13):1515-7. doi: 10.1016/j.vaccine.2015.01.085. epub 2015
feb 11.

the immunogenicity safety zoster vaccine taiwanese adults.

yao ca(1), chen lk(2), huang kc(3).

author information: 
(1)department family medicine, national taiwan university hospital, taipei,
taiwan.
(2)department family medicine, taipei veterans general hospital, taipei,
taiwan. electronic address: lkchen2@vghtpe.gov.tw.
(3)department family medicine, national taiwan university hospital, taipei,
taiwan. electronic address: bretthuang@ntu.edu.tw.

the efficacy safety zostavax subjects 60 years age older was
established shingles prevention study (sps) subjects 50 59 years
of age zostavax efficacy safety trial (zest). evaluated safety 
and immunogenicity zostavax total 150 taiwanese subjects ≥50 years 
age, received single dose zostavax. gpelisa used determine
geometric mean titers (gmt) varicella-zoster virus (vzv) antibody. the
geometric mean fold rise (gmfr) vzv antibody pre-vaccination to
the 4 week post-vaccination time point calculated. overall
increase gmt 128.45 391.85 4 weeks post-vaccination. estimated 
gmfr 3.05 (95% ci: 2.60 3.57).there serious adverse events 28 
days following vaccination. study demonstrated safety immunogenicity
of zostavax among healthy taiwanese adults.

copyright © 2015 elsevier ltd. rights reserved.

doi: 10.1016/j.vaccine.2015.01.085 
pmid: 25681662  [indexed medline]

